Press release
Biosimilar Market Analysis, Growth Report, Key Factor, Top Companies and Revenue 2023-2028
The global biosimilar market size reached US$ 16.8 Billion inย 2022. Looking forward, IMARC Group expects the market to reach US$ 77.1 Billion byย 2028, exhibiting a growth rate (CAGR) of 25.9% duringย 2023-2028.ย
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐จ๐ซ ๐๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐จ๐ ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.imarcgroup.com/biosimilar-market/requestsample
What are Biosimilars services?
Biosimilars are medical products highly similar to an already-approved biological product, known as the "reference product," in terms of safety, purity, and efficacy. They are derived from living organisms, such as cells and tissues, and are commonly used for the treatment of various diseases, including cancer, diabetes, and autoimmune disorders. Due to their complex nature and manufacturing process, biosimilars offer an alternative, usually at a lower cost, without compromising on the quality and efficacy of treatment.
What are the growth prospects and trends in the Biosimilars industry?
The rise in chronic diseases and the growing emphasis on cost-effective treatment options are fueling the demand for biosimilars. Their affordability compared to reference biological products serves as a significant driver of market growth. Furthermore, the expiration of patents for multiple blockbuster biological drugs is paving the way for the entry of biosimilars, thereby expanding market opportunities. Manufacturers are investing in research and development to match the safety and efficacy of reference biological products, which, in turn, supports market growth. Regulatory approvals also play a crucial role; streamlined guidelines from health authorities can expedite the introduction of new biosimilars to the market.
Besides their use in treating chronic diseases, biosimilars are also gaining traction in preventive medicine. For instance, biosimilar vaccines are being developed to combat a range of infectious diseases, thereby broadening their consumer base and contributing to market expansion. Specialized companies that focus on the development of high-quality biosimilars are enhancing their portfolios, aiming to offer effective yet affordable solutions for both common and rare diseases. Distribution channels for biosimilars include pharmacies, healthcare providers, and online platforms specializing in healthcare products. Additionally, their increasing adoption in emerging markets, where the focus on affordable healthcare solutions is intense, further propels market growth.
Who are the key players operating in the Biosimilars industry?
The report covers the major market players including:ย
Novartis
Pfizer
Teva
Celltrion
Merck & Co
Samsung Bioepis
Eli Lilly
Biocon
Reddy's Laboratories
Amgen
Boehringer Ingelheim
What is included in market segmentation?
The report has segmented the market into the following categories:
Molecule insights:ย
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Indication Insights:
Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Manufacturing Insights:
In-house Manufacturing
Contract Manufacturing
Regional Insights:
United States
Germany
France
Italy
Spain
United Kingdom
Japan
India
South Korea
Others
๐๐ฉ๐๐๐ค ๐ญ๐จ ๐๐ง ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ญ ๐จ๐ซ ๐๐๐ญ ๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง ๐๐๐จ๐ฎ๐ญ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.imarcgroup.com/request?type=report&id=497&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email:ย sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Market Analysis, Growth Report, Key Factor, Top Companies and Revenue 2023-2028 here
News-ID: 3240454 • Views: โฆ
More Releases from IMARC Group
Automotive Control Cables Manufacturing Plant Setup Report 2025: Machinery, Raw โฆ
Automotive control cables are essential components used to transmit mechanical force in vehicles, enabling the smooth operation of various systems such as brakes, clutches, accelerators, gear shifts, and seating mechanisms. These cables are designed for durability, flexibility, and high performance under diverse driving conditions. Their demand is directly linked to the growth of the automotive industry, aftermarket sales, and increasing consumer preference for enhanced driving comfort and safety.
Setting up anโฆ
Halal Cosmetics Market Size, Trends, Key Players, Opportunity and Forecast 2025- โฆ
IMARC Group, a leading market research company, has recently released a report titled "Halal Cosmetics Market Size, Share, Trends and Forecast by Type, Distribution Channel, and Region, 2025-2033." The study provides a detailed analysis of the industry, including the global halal cosmetics market size, trends, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Halal Cosmetics Market Highlights:
โข Halal Cosmetics Marketโฆ
Comprehensive Castor Oil Processing Plant Project Report 2025: Setup Guide, Econ โฆ
Castor oil is a versatile vegetable oil extracted from the seeds of the Ricinus communis plant. It is widely used in pharmaceuticals, cosmetics, food processing, lubricants, paints, coatings, and biodiesel production owing to its unique chemical properties, including high ricinoleic acid content. Castor oil derivatives also serve as key raw materials in the polymer, chemical, and industrial sectors.
Establishing a castor oil processing plant involves steps such as seed cleaning, dehulling,โฆ
Honey Processing Plant Report 2025: Capital Investment, Operating Expenses and M โฆ
Honey is a natural sweetener produced by honeybees and is valued for its nutritional, medicinal, and industrial applications. It contains antioxidants, enzymes, vitamins, and minerals that make it a popular ingredient in food and beverages, pharmaceuticals, cosmetics, and personal care products. Processed honey is widely consumed as a sweetener, used in bakery and confectionery items, beverages, dietary supplements, and skincare formulations.
Setting up a honey processing plant involves operations such asโฆ
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance โฆ
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financialโฆ
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance โฆ
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financialโฆ
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark โฆ
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Getโฆ
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02โฆ
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning ofโฆ
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning ofโฆ
